Recce Pharmaceuticals Ltd

ASX:RCE Stock Report

Market Cap: AU$103.2m

Recce Pharmaceuticals Management

Management criteria checks 2/4

Recce Pharmaceuticals' CEO is James Graham, appointed in Aug 2020, has a tenure of 4.33 years. total yearly compensation is A$834.51K, comprised of 62.8% salary and 37.2% bonuses, including company stock and options. directly owns 2.92% of the company’s shares, worth A$3.01M. The average tenure of the management team and the board of directors is 4.3 years and 6 years respectively.

Key information

James Graham

Chief executive officer

AU$834.5k

Total compensation

CEO salary percentage62.8%
CEO tenure4.3yrs
CEO ownership2.9%
Management average tenure4.3yrs
Board average tenure6yrs

Recent management updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Recent updates

We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Nov 01
We Think Shareholders Are Less Likely To Approve A Pay Rise For Recce Pharmaceuticals Ltd's (ASX:RCE) CEO For Now

Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

Feb 13
Here's Why We're Watching Recce Pharmaceuticals' (ASX:RCE) Cash Burn Situation

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Jul 28
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Dec 07
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Aug 03
We're Hopeful That Recce Pharmaceuticals (ASX:RCE) Will Use Its Cash Wisely

Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Mar 08
Recce Pharmaceuticals (ASX:RCE) Is In A Good Position To Deliver On Growth Plans

Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Feb 01
Need To Know: Recce Pharmaceuticals Ltd (ASX:RCE) Insiders Have Been Selling Shares

Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

Dec 09
Could The Recce Pharmaceuticals Ltd (ASX:RCE) Ownership Structure Tell Us Something Useful?

CEO Compensation Analysis

How has James Graham's remuneration changed compared to Recce Pharmaceuticals's earnings?
DateTotal CompensationSalaryCompany Earnings
Jun 30 2024AU$835kAU$524k

-AU$18m

Mar 31 2024n/an/a

-AU$14m

Dec 31 2023n/an/a

-AU$11m

Sep 30 2023n/an/a

-AU$12m

Jun 30 2023AU$775kAU$551k

-AU$13m

Mar 31 2023n/an/a

-AU$14m

Dec 31 2022n/an/a

-AU$15m

Sep 30 2022n/an/a

-AU$13m

Jun 30 2022AU$548kAU$328k

-AU$11m

Mar 31 2022n/an/a

-AU$10m

Dec 31 2021n/an/a

-AU$8m

Sep 30 2021n/an/a

-AU$11m

Jun 30 2021AU$2mAU$294k

-AU$14m

Mar 31 2021n/an/a

-AU$13m

Dec 31 2020n/an/a

-AU$13m

Sep 30 2020n/an/a

-AU$9m

Jun 30 2020AU$216kAU$187k

-AU$4m

Mar 31 2020n/an/a

-AU$4m

Dec 31 2019n/an/a

-AU$3m

Sep 30 2019n/an/a

-AU$3m

Jun 30 2019AU$177kAU$155k

-AU$3m

Mar 31 2019n/an/a

-AU$2m

Dec 31 2018n/an/a

-AU$2m

Sep 30 2018n/an/a

-AU$2m

Jun 30 2018AU$160kAU$142k

-AU$2m

Compensation vs Market: James's total compensation ($USD521.93K) is above average for companies of similar size in the Australian market ($USD291.28K).

Compensation vs Earnings: James's compensation has increased whilst the company is unprofitable.

CEO

James Graham

4.3yrs

Tenure

AU$834,509

Compensation

Mr. James Hamilton-Bray Graham, B.Com. (Entrepreneurship), GAICD, serves as Chief Executive Officer at Recce Pharmaceuticals Ltd since August 28, 2020 and also serves as Managing Director since 2020. He ha...

Leadership Team

NamePositionTenureCompensationOwnership
John K. Prendergast
Executive Chairman of the Board6.7yrsAU$380.55k0.13%
A$ 136.5k
James Graham
CEO, MD & Executive Director4.3yrsAU$834.51k2.92%
A$ 3.0m
Michele Dilizia
Chief Scientific Director & Executive Director4.3yrsAU$530.84k1.17%
A$ 1.2m
Justin Ward
Principal Quality Chemist & Executive Directorno dataAU$318.53k0.13%
A$ 134.1k
Arthur Kollaras
Principal Engineer & Head of Manufacturingno dataAU$564.01k0.040%
A$ 41.0k
Alan Dunton
Chief Medical Advisor & Independent Non Executive Directorno dataAU$75.00k0.055%
A$ 56.4k
Justin Reynolds
Chief Financial Officer7.1yrsno datano data
Daniel Astudillo
Head of Marketing4.9yrsno datano data
Maggie Niewidok
Company Secretary2.3yrsno datano data

4.3yrs

Average Tenure

Experienced Management: RCE's management team is considered experienced (4.3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
John K. Prendergast
Executive Chairman of the Board6.7yrsAU$380.55k0.13%
A$ 136.5k
James Graham
CEO, MD & Executive Director9.5yrsAU$834.51k2.92%
A$ 3.0m
Michele Dilizia
Chief Scientific Director & Executive Director9.5yrsAU$530.84k1.17%
A$ 1.2m
Justin Ward
Principal Quality Chemist & Executive Director5.4yrsAU$318.53k0.13%
A$ 134.1k
Alan Dunton
Chief Medical Advisor & Independent Non Executive Director4.4yrsAU$75.00k0.055%
A$ 56.4k
Alistair McKeough
Non-Executive Director2.3yrsAU$81.25k0.011%
A$ 11.6k

6.0yrs

Average Tenure

Experienced Board: RCE's board of directors are considered experienced (6 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 05:41
End of Day Share Price 2024/12/20 00:00
Earnings2024/06/30
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Recce Pharmaceuticals Ltd is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Pooya HemamiEdison Investment Research
Chris KallosMST Financial Services Pty Limited